|
Press Releases |
|
|
|
Friday, October 25, 2024 |
|
HighTide Therapeutics to Present Analyses of Phase 2 MASH Study at AASLD's The Liver Meeting 2024 |
HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, will present at the American Association for the Study of Liver Diseases' (AASLD) The Liver Meeting, taking place from November 15-19, 2024 in San Diego, California. more info >> |
|
Wednesday, September 11, 2024 |
|
EASD 2024 | HighTide Therapeutics Presents Oral Reports of Phase 2 Studies, Highlighting Benefits of Berberine Ursodeoxycholate (HTD1801) |
HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multifunctional multi-targeted therapies for chronic liver and metabolic diseases, presents at the 60th European Association for the Study of Diabetes (EASD) Annual Meeting, taking place from September 10-13, 2024 in Madrid, Spain. more info >> |
|
Friday, June 21, 2024 |
|
HighTide Therapeutics Presents Analyses of a Phase 2 T2DM Study at the ADA Scientific Sessions, Highlighting Glycemic and Cardiometabolic Benefits of Berberine Ursodeoxycholate (HTD1801) |
HighTide Therapeutics, Inc. (2511.HK), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced today that it will present at the American Diabetes Association's (ADA) 84th Scientific Sessions, taking place from June 21-24, 2024 in Orlando, Florida. more info >> |
|
Wednesday, June 5, 2024 |
|
HighTide Therapeutics Presents Analyses of Phase 2a MASH Study at the 2024 International Liver Congress, Reinforcing and Further Characterizing the Efficacy and Safety of Berberine Ursodeoxcyholate (HTD1801) |
HighTide Therapeutics, Inc. (HKEX: 2511), a clinical stage biopharmaceutical company specializing in the development of multi-targeted therapies for chronic liver and metabolic diseases, announced that it will make multiple presentations at the European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024 in Milan, Italy. more info >> |
|
Wednesday, January 11, 2023 |
|
HighTide Therapeutics Announces First Patient Dosed in Phase 2b Clinical Study Evaluating HTD1801 in NASH (the CENTRICITY study) |
HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the dosing of the first patient in a Phase 2b clinical study evaluating HTD1801 for the treatment of nonalcoholic steatohepatitis ("NASH"). more info >> |
|
Thursday, January 5, 2023 |
|
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing to Advance Innovative Pipeline and Business Collaborations |
HighTide Therapeutics Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases more info >> |
|
Thursday, November 17, 2022 |
|
AJG Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis |
HighTide Therapeutics, Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced the publication of the results of their Phase 2 study of HTD1801 in adults with primary sclerosing cholangitis (PSC) in the American Journal of Gastroenterology. more info >> |
|
Wednesday, November 16, 2022 |
|
American Journal of Gastroenterology Publishes Data from HighTide Therapeutics' Phase 2 Study of HTD1801 Treatment in Primary Sclerosing Cholangitis |
HighTide Therapeutics, Inc. ("HighTide"), a globally integrated clinical-stage biopharmaceutical company developing novel multifunctional therapies for metabolic and digestive diseases, today announced publication of the results of their Phase 2 study of HTD1801 in adults with primary sclerosing cholangitis (PSC) in the American Journal of Gastroenterology. more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Military Metals Appoints DGWA as European Financial Markets Advisor
Feb 5, 2025 21:39 HKT/SGT
|
|
|
Doubleview Gold Corp Increases the Dimensions of the Hat Polymetallic Deposit with High-Grade and Extensive Mineralization in Drill Holes H075 to H077
Feb 5, 2025 18:59 HKT/SGT
|
|
|
Approval in Principle (AiP) Acquired from Classification Society for Low-Pressure Type Coastal Liquefied CO2 Carrier
Feb 5, 2025 17:46 JST
|
|
|
Toyota Powers On New North Carolina Automotive Battery Plant
Feb 5, 2025 13:59 JST
|
|
|
Toyota to Form Comprehensive Partnership on Carbon Neutrality with Shanghai and Establish a Company to Develop and Produce BEVs and Batteries
Feb 5, 2025 13:56 JST
|
|
|
Fujitsu to highlight AI-powered network technologies at MWC Barcelona 2025
Feb 5, 2025 10:25 JST
|
|
|
QSEC-CEE 2025 Concludes with Breakthroughs in Quantum Cybersecurity
Feb 4, 2025 20:00 HKT/SGT
|
|
|
Mallia Therapeutics and Northway Biotech Announce Partnership for the Manufacturing of Soluble CD83 Protein for Hair Loss Treatment
Feb 4, 2025 18:00 HKT/SGT
|
|
|
TOYOTA GAZOO Racing Launches Evolved GR Corolla in Japan
Feb 4, 2025 18:41 JST
|
|
|
Mitsubishi Heavy Industries Achieves Double-Digit Order Intake and Profit Growth in First Three Quarters, Raises Full-Year Guidance
Feb 4, 2025 18:34 JST
|
|
|
MAZDA TRANS AOYAMA Opens in Minami-Aoyama
Feb 4, 2025 17:38 JST
|
|
|
Fujitsu launches gen AI software analysis and visualization service to support optimal modernization planning
Feb 4, 2025 11:39 JST
|
|
|
CyberX Summit & Awards 2025: Qatar Edition to Gather Top Cybersecurity Experts
Feb 4, 2025 09:07 HKT/SGT
|
|
|
Renewable Energy Power Purchase Agreements: Analyzing, Structuring, and Negotiating for Bankable Green Investments in Competitive Markets
Feb 4, 2025 09:00 HKT/SGT
|
|
|
Arctic Wolf and BlackBerry Announce Closing of Acquisition for Cylance
Feb 4, 2025 08:00 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|